GSK PLC

GSK: XLON (GBR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|V^LOCK|f^LOCK|%%PYnD

GSK Earnings: Another Strong Quarter for Vaccines, Three-Year Restructuring Program Announced

GSK reported 5% year-over-year revenue growth at constant currency and a 33.3% core operating margin. Management reaffirmed full-year guidance and announced a three-year restructuring program to cut annual operating expense by GBP 1.9 billion to fund late-stage pipeline and research and development.

Sponsor Center